Loading…
Employees: 506
Size Cosmecca Korea (241710.KS) is a South Korea Consumer Staples company (Household/Personal Care) with a market value of $798M, the 265th largest of 495 South Korea companies the cockpit tracks. Shares closed at ₩101,400 on 6 Nov 2026.
Performance Over six months the shares gained 25.2%, against -9.2% for the median peer and -24.5% for the South Korea market (cap-weighted) — 5th highest of 21 in its peer set.
Growth Revenue grew 44.3% over the last twelve months (peer median +8.3%); the operating margin is 12.9% (peer median 8.2%).
Valuation It trades at 14.4× forward earnings against a peer median of 19.6× (5th cheapest of 20).
Price implies For today's price to make sense, revenue must grow about -6% a year for seven years (Req g). Recent delivered growth is +14%, so the hurdle is -19 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 8.4 points above its cost of capital (5.3% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩772B | ₩641B | ₩524B | ₩471B | ₩399B |
| Revenue growth | — | +22% | +11% | +18% | — |
| Gross profit | ₩179B | ₩155B | ₩119B | ₩102B | ₩59.8B |
| EBITDA | ₩117B | ₩100B | ₩78.2B | ₩65.8B | ₩27.1B |
| Net income | ₩63.8B | ₩45.4B | ₩42.8B | ₩22.3B | ₩2.66B |
| Free cash flow | ₩6.03B | -₩6.34B | ₩20.8B | ₩23.4B | ₩5.12B |
| Capital expenditure | ₩49.7B | ₩61.5B | ₩49.0B | ₩18.7B | ₩11.8B |
| Total debt | ₩233B | ₩172B | ₩122B | ₩109B | ₩121B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 241710.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -13.3% | -7.9% | 8th lowest of 21 |
| 6-month return | +25.2% | -9.2% | 5th highest of 21 |
| Distance from 52-week high | -34.8% | -34.8% | 11th highest of 21 |
| Revenue growth (TTM) | +44.3% | +8.3% | 4th highest of 21 |
| Operating margin | 12.9% | 8.2% | 6th highest of 21 |
| Forward P/E | 14.4× | 19.6× | 5th cheapest of 20 |
| Growth the price implies (Req g, 7 yrs) | -5.9% | 4.2% | least demanding of 17 |
| Growth delivered (Del g) | +13.6% | +8.5% | 7th highest of 17 |
| Hurdle (Req g minus delivered) | -19.5 pp | -3.4 pp | 5th least demanding of 17 |
| ROIC minus cost of capital | +8.4 pp | +5.5 pp | 8th highest of 21 |
| EV / EBITDA | 11.0× | 11.2× | 7th cheapest of 13 |
| Net debt / EBITDA | 1.2× | -1.4× | 3rd most indebted of 14 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Cosmecca Korea 241710.KS | South Korea | $798M | +25% | +44% | 13% | 14.4× | -5.9% | +13.6% |
| Galaxy Surfactants GALAXYSURF.NS | India | $819M | +13% | +30% | 9% | 18.6× | 18.0% | +13.7% |
| Jyothy Labs JYOTHYLAB.NS | India | $773M | -23% | +5% | 8% | 30.9× | 35.0% | +8.9% |
| Hangzhou Haoyue Personal Care 605009.SS | China | $750M | -19% | +10% | 6% | 17.7× | 4.7% | +7.7% |
| Runben Biotechnology 603193.SS | China | $940M | -33% | +13% | 21% | 18.9× | 1.7% | +28.4% |
| Dencare (Chongqing) Oral Care 001328.SZ | China | $944M | +15% | +10% | 11% | 28.9× | 4.3% | +10.8% |
| Milbon 4919.T | Japan | $669M | +30% | +6% | 13% | 22.9× | -3.1% | +8.2% |
| Tongling Jieya Biologic Technology 301108.SZ | China | $961M | +47% | +54% | 7% | 54.0× | n/a | n/a |
| Noevir 4928.T | Japan | $977M | +3% | +1% | 16% | 19.4× | -4.8% | +4.5% |
| SYoung 300740.SZ | China | $1.00B | -37% | +14% | 3% | 39.6× | 18.1% | +6.1% |
| Shanghai Forest Cabin Cosmetics 2657.HK | Hong Kong | $1.06B | 0% | +74% | 18% | 12.1× | 11.5% | +49.0% |
| PZ Cussons PZC.L | United Kingdom | $566M | +30% | +5% | 11% | 13.3× | -1.7% | -2.1% |
| Bajaj Consumer Care BAJAJCON.NS | India | $551M | -24% | +29% | 22% | 19.6× | 14.6% | +5.0% |
| Shanghai Chicmax Cosmetics 2145.HK | Hong Kong | $1.22B | -52% | +23% | 8% | 15.0× | -5.9% | +21.2% |
| Edgewell Personal Care EPC | United States | $1.29B | +32% | -7% | 6% | 12.4× | 4.1% | +2.7% |
| d'Alba Global 483650.KS | South Korea | $1.32B | -37% | +55% | 21% | 13.6× | -2.2% | +53.0% |
| Qingdao Kingking Applied Chemistry 002094.SZ | China | $464M | -25% | -7% | 4% | n/a | n/a | n/a |
| Tianjin Yiyi Hygiene Products 001206.SZ | China | $448M | -15% | -8% | 9% | 20.8× | 2.5% | +6.3% |
| Lafang China 603630.SS | China | $445M | -20% | -3% | 2% | 40.4× | n/a | n/a |
| Guangdong Marubi Biotechnology 603983.SS | China | $1.45B | -4% | -6% | 2% | 37.0× | n/a | n/a |
| Chongqing Baiya Sanitary Products 003006.SZ | China | $1.49B | +25% | 0% | 3% | 41.2× | 30.6% | +22.8% |